Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

  • Passaro, A.; 
  • Wang, J.; 
  • Wang, Y.; 
  • Lee, S. -H.; 
  • Melosky, B.; 
  • 외 37명
Citations

WEB OF SCIENCE

442
Citations

SCOPUS

484

초록

Background: Amivantamab plus carboplatin-pemetrexed (chemotherapy) with and without lazertinib demonstrated antitumor activity in patients with refractory epidermal growth factor receptor (EGFR)-mutated advanced non-smallcell lung cancer (NSCLC) in phase I studies. These combinations were evaluated in a global phase III trial. Patients and methods: A total of 657 patients with EGFR-mutated (exon 19 deletions or L858R) locally advanced or metastatic NSCLC after disease progression on osimertinib were randomized 2 : 2 : 1 to receive amivantamab - lazertinib-chemotherapy, chemotherapy, or amivantamab-chemotherapy. The dual primary endpoints were progression-free survival (PFS) of amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy. During the study, hematologic toxicities observed in the amivantamab-lazertinib-chemotherapy arm necessitated a regimen change to start lazertinib after carboplatin completion. Results: All baseline characteristics were well balanced across the three arms, including by history of brain metastases and prior brain radiation. PFS was significantly longer for amivantamab-chemotherapy and amivantamab-lazertinib - chemotherapy versus chemotherapy [hazard ratio (HR) for disease progression or death 0.48 and 0.44, respectively; P < 0.001 for both; median of 6.3 and 8.3 versus 4.2 months, respectively]. Consistent PFS results were seen by investigator assessment (HR for disease progression or death 0.41 and 0.38 for amivantamab -chemotherapy and amivantamab-lazertinib-chemotherapy, respectively; P < 0.001 for both; median of 8.2 and 8.3 versus 4.2 months, respectively). Objective response rate was significantly higher for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy (64% and 63% versus 36%, respectively; P < 0.001 for both). Median intracranial PFS was 12.5 and 12.8 versus 8.3 months for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy (HR for intracranial disease progression or death 0.55 and 0.58, respectively). Predominant adverse events (AEs) in the amivantamab-containing regimens were hematologic, EGFR-, and MET -related toxicities. Amivantamab-chemotherapy had lower rates of hematologic AEs than amivantamab-lazertinib-chemotherapy. Conclusions: Amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy improved PFS and intracranial PFS versus chemotherapy in a population with limited options after disease progression on osimertinib. Longer follow-up is needed for the modified amivantamab-lazertinib-chemotherapy regimen.

키워드

amivantamab; lazertinib; EGFR-mutated; NSCLC; post-osimertinib; CELL LUNG-CANCER; RESISTANCE; MECHANISMS
제목
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
저자
Passaro, A.; Wang, J.; Wang, Y.; Lee, S. -H.; Melosky, B.; Shih, J. -Y.; Wang, J.; Azuma, K.; Juan-Vidal, O.; Cobo, M.; Felip, E.; Girard, N.; Cortot, A. B.; Califano, R.; Cappuzzo, F.; Owen, S.; Popat, S.; Tan, J. -l.; Salinas, J.; Tomasini, P.; Gentzler, R. D.; William, W. N.; Reckamp, K. L.; Takahashi, T.; Ganguly, S.; Kowalski, D. M.; Bearz, A.; MacKean, M.; Barala, P.; Bourla, A. B.; Girvin, A.; Greger, J.; Millington, D.; Withelder, M.; Xie, J.; Sun, T.; Shah, S.; Diorio, B.; Knoblauch, R. E.; Bauml, J. M.; Campelo, R. G.; Cho, B. C.
DOI
10.1016/j.annonc.2023.10.117
발행일
2024-01
유형
Article
저널명
Annals of Oncology
권
35
호
1
페이지
77 ~ 90